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It is clearly an ambitious undertaking to write a book
titled “Cellular Cancer Markers” when both the basic
research within this field and related clinical applica-
tions are growing so rapidly. In this field where new
genes and cellular mechanisms are being described in
nearly every periodical focusing on cancer and/or ge-
netic research, it should be expected that such a book
would be at least somewhat “out-of-date” prior to its re-
lease, giving it a limited “shelf-life.” Clearly, this book
(published in 1995) does not contain, nor should one ex-
pect it to contain, the latest information in the cellular
and molecular biology of cancer. The editors of this
book, Drs. C.T. Garrett and S. Sell, both widely pub-
lished in this field, clearly recognized this challenge
and wisely chose to limit their text to a small number of
well-characterized topics in the field while addressing
potential future directions of this field. In addition,
their final chapter, Chapter 17—“Summary and Per-
spective: Assessing Test Effectiveness—the Identifica-
tion of Good Tumor Markers,” is essentially timeless as
a general discussion about the qualities of a good can-
cer marker, including excellent discussions of sensitiv-
ity, specificity, and cost-effectiveness.
Our increased understanding of the molecular and
cellular mechanisms underlying human malignancy
has ushered in an exciting new era in molecular oncol-
ogy. Information gained through basic research over
the past decade has been making its way into the clini-
cal arena for presymptomatic risk assessment, diag-
nostic testing, prognostic evaluations, and therapeutic
strategies for a wide variety of malignancies. It is likely
that this translation of basic science research to clinical
applications will continue to increase, fostering rapidly
expanding, profitable biotechnology enterprises. As ge-
neticists, it is likely that we will be faced with increas-
ing questions from our colleagues and patients regard-
ing cancer risks and potential molecular genetic
strategies for evaluation and management. Therefore,
although this book is geared toward pathologists, on-
cologists, and laboratory medicine physicians and sci-
entists, it covers an area in medicine that is increas-
ingly important for all health care professionals and
scientists studying human disease. Anyone who has a
basic background understanding of cancer genetics and
cellular biology would be able to appreciate the content
of this book.
The book contains 484 pages and consists of 17 chap-
ters to which 35 different authors have contributed
their individual expertise. After an informative intro-
ductory chapter, “Clinical Application of Genetic, Onco-
genic, and Differentiation Markers of Cancer,” which
uses breast cancer as an example to highlight some
general concepts of cellular cancer markers, the next
three chapters focus on one specific, relatively well-
characterized molecular genetic marker, including a
chapter on each of the following—ras, p53, and C-myc.
The following eight chapters then look at these and
other markers specifically as related to a particular
body system or organ. Chapters focus on gynecological
malignancies, colon cancer, breast cancer, lung cancer,
Wilms tumor, non-Hodgkin’s lymphomas, Hodgkin’s
disease, melanoma, and minimal residual disease of
leukemia and lymphoma. The remaining three chap-
ters preceding the concluding chapter address some
molecular mechanisms that have already contributed
to, or have potential future promise to play a key role
in, the therapy of malignancy. These chapters contain
information about P-glycoproteins, antitumor mono-
clonal antibodies, and antisense oligonucleotides.
One strength of this book is that all of the chapters
are relatively comprehensive, clearly written, and can
stand alone. The level of detailed knowledge reflects
the individual expertise of the many different authors.
The multiauthorship nature of the book, however, is
also one of the downfalls of this book. There is redun-
dancy in the presentation of background information
(such as Knudson’s two-hit hypotheses of tumor sup-
pressor genes) and also in some of the specific informa-
tion. This also weakens the organization of the book.
For instance, information about cellular cancer mark-
ers in breast cancer is obviously included in the well-
written chapter devoted entirely to breast cancer
(Chapter 7). Additional relevant (but somewhat redun-
dant) information about breast cancer, however, is in-
cluded in three other chapters—the introductory first
chapter, the chapter devoted to p53 (Chapter 4), and
the chapter focusing on C-myc (Chapter 3). The overall
quality of the individual chapters is variable. Although
the majority of the chapters have clearly written text
and are well referenced, there are clear discrepancies
among authors regarding the use of figures and tables.
For instance, Chapter 16, “Targeting Antisense
Oligonucleotide Chemotherapy to the Type I Regula-
tory Subunit of cAMP-Dependent Protein Kinase” by
Yoon Sang Cho-Chung, would have been more appeal-
ing to me if it had a few more figures to illustrate the
main points of the text. Chapter 6, “Genetic Alterations
in Colon Cancer,” which is very well written and exten-
sively referenced by Sunhail Nasin and Careleton T.
Garrett, contains 36 pages of comprehensive text with
only two general, relatively generic, introductory tables
in the entire chapter. Readers, including myself, who
benefit from the visual presentation of information
and/or strongly believe in the powerful utility of clear
tables and figures, are left somewhat disappointed by
the lack of good figures and tables in some of the chap-
underlying carcinogenesis. Certainly any laboratory-
based geneticist who is interested in developing molec-
ular tests for cancer should at least take a look at this
book and at least read through the final chapter. How-
ever, individuals interested in learning about the most
recent developments regarding molecular mechanisms
involved in a particular malignancy or a favorite cancer
gene would be better served by reading recent journal
articles.
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ters. Additionally, although it should be anticipated
that some of the information presented in this book will
be out-of-date, there are differences among chapters re-
garding how current the information is. For instance,
in the chapter on breast cancer, information that was
published in the fall of 1994 regarding the cloning and
characterization of BRCA1 and mapping of BRCA2 is
included. However, in the chapter on melanoma, no in-
formation about p16/MTS1/CDNK2 is presented—in-
formation that was first published in the spring of
1994, several months before the BRCA1 cloning and
BRCA2 mapping papers.
Overall, this book is relatively good for the diversity
and detail of subject matter. It may be useful to the
readers of this journal who want to increase their gen-
eral knowledge of molecular and cellular mechanisms
